European Journal of Haematology最新文献_第3页

Safety of Crovalimab Versus Eculizumab in Patients With Paroxysmal Nocturnal Haemoglobinuria (PNH): Pooled Results From the Phase 3 COMMODORE Studies. Crovalimab与Eculizumab对阵发性夜间血红蛋白尿症（PNH）患者的安全性对比：COMMODORE 3 期研究的汇总结果。

IF 2.3 3区医学

European Journal of Haematology Pub Date : 2024-11-13 DOI: 10.1111/ejh.14339

Alexander Röth, Rong Fu, Guangsheng He, Hazzaa Alzahrani, Sheng-Chieh Chou, Yosr Hicheri, Maciej Kaźmierczak, Viviane Lacorte Recova, Michihiro Uchiyama, Ana-Maria Vladareanu, Leigh Beveridge, Simon Buatois, Muriel Buri, Nicolo Compagno, Dayu Shi, Nadiesh Balachandran, Sasha Sreckovic, Phillip Scheinberg

{"title":"Safety of Crovalimab Versus Eculizumab in Patients With Paroxysmal Nocturnal Haemoglobinuria (PNH): Pooled Results From the Phase 3 COMMODORE Studies.","authors":"Alexander Röth, Rong Fu, Guangsheng He, Hazzaa Alzahrani, Sheng-Chieh Chou, Yosr Hicheri, Maciej Kaźmierczak, Viviane Lacorte Recova, Michihiro Uchiyama, Ana-Maria Vladareanu, Leigh Beveridge, Simon Buatois, Muriel Buri, Nicolo Compagno, Dayu Shi, Nadiesh Balachandran, Sasha Sreckovic, Phillip Scheinberg","doi":"10.1111/ejh.14339","DOIUrl":"https://doi.org/10.1111/ejh.14339","url":null,"abstract":"Objectives: To evaluate the tolerability of crovalimab versus eculizumab in C5 inhibitor (C5i)-naive and -experienced patients with PNH from COMMODORE 2, 3 and 1 (NCT04434092, NCT04654468 and NCT04432584).Methods: Pooled safety data were assessed in the total crovalimab and eculizumab populations and by C5i-naive versus C5i-switched status in patients receiving crovalimab. Analyses include 6.5 months of additional follow-up from the COMMODORE 2 and 1 primary analyses.Results: COMMODORE safety data (crovalimab, 393 patients [naive, 192 patients; switched, 201 patients]; eculizumab, 111 patients) were analysed. The total patient years (PY) were 503.9 and 51.1 in the total crovalimab and eculizumab populations, respectively, with 471 and 581 adverse events (AEs) per 100 PY. Serious infection rates were 8.9 and 13.7 AEs per 100 PY, respectively; no meningococcal infections were reported. Fatal AEs occurred in eight (2%) patients receiving crovalimab (naive, six patients; switched, two patients) and one (1%) receiving eculizumab, all treatment unrelated. In C5i-switched patients, 39 (19%) had transient immune complex reactions (risk when switching between C5i and crovalimab); the majority were Grades 1-2 arthralgia and rash, and 16 (8%) had Grade 3 events.Conclusions: Crovalimab's safety profile was consistent with eculizumab's and was generally comparable between C5i-naive and C5i-switched patients.","PeriodicalId":11955,"journal":{"name":"European Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142617517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Allogeneic Hematopoietic Stem Cell Transplantation in Refractory Multiple Myeloma-A Retrospective Multicenter Analysis. 异基因造血干细胞移植治疗难治性多发性骨髓瘤--一项多中心回顾性分析。

IF 2.3 3区医学

European Journal of Haematology Pub Date : 2024-11-13 DOI: 10.1111/ejh.14346

T Richardson, G Kobbe, R Fenk, T Schroeder, M Crysandt, C Neuerburg, Tobias A W Holderried, D Schütte, P Gödel, M Hallek, C Scheid, U Holtick

{"title":"Allogeneic Hematopoietic Stem Cell Transplantation in Refractory Multiple Myeloma-A Retrospective Multicenter Analysis.","authors":"T Richardson, G Kobbe, R Fenk, T Schroeder, M Crysandt, C Neuerburg, Tobias A W Holderried, D Schütte, P Gödel, M Hallek, C Scheid, U Holtick","doi":"10.1111/ejh.14346","DOIUrl":"https://doi.org/10.1111/ejh.14346","url":null,"abstract":"A growing list of therapies available for patients with multiple myeloma (MM) results in deep response rates, but eventually almost all patients relapse. Allogeneic hematopoietic cell transplantation (allo-SCT) is a familiar approach for MM, but responses are often short and side effects burdensome. Simultaneously, allo-SCT provides a unique platform on which novel immune therapies can be employed to improve clinical outcomes. Our work describes the characteristics and outcomes of 128 refractory myeloma patients who underwent allo-SCT at five German centers between 2010 and 2021. The median number of therapies before the transplant was 6. With a median follow-up of 6, 4 years, the median progression-free survival and overall survival were 7 and 19 months, respectively. NRM was 28% after 6 years. OS and PFS were 61% and 45% at 1 year, 49% and 34% at 2 years, and 38% and 25% at 6 years. Achieving a CR before transplant was the single most significant variable before transplant. Allo-SCT yet remains an option for fit patient's refractory to all other treatments available. It is potentially curative for a subset of patients. Finding the characteristics of patients with durable remissions is key to sparing unnecessary toxicity for those unlikely to benefit.","PeriodicalId":11955,"journal":{"name":"European Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142617478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Delineating Notch1 and Notch2: Receptor-Specific Significance and Therapeutic Importance of Pinpoint Targeting Strategies for Hematological Malignancies. 划分 Notch1 和 Notch2：Notch1和Notch2：受体特异性意义和血液恶性肿瘤精确靶向策略的治疗重要性。

IF 2.3 3区医学

European Journal of Haematology Pub Date : 2024-11-12 DOI: 10.1111/ejh.14312

Priyadharshini Tamizhmani, Banumathi Balamurugan, Kishore Thirunavukarasu, Velayuthaprabhu Shanmugam, Selvakumar Subramaniam, Thirunavukkarasu Velusamy

{"title":"Delineating Notch1 and Notch2: Receptor-Specific Significance and Therapeutic Importance of Pinpoint Targeting Strategies for Hematological Malignancies.","authors":"Priyadharshini Tamizhmani, Banumathi Balamurugan, Kishore Thirunavukarasu, Velayuthaprabhu Shanmugam, Selvakumar Subramaniam, Thirunavukkarasu Velusamy","doi":"10.1111/ejh.14312","DOIUrl":"https://doi.org/10.1111/ejh.14312","url":null,"abstract":"Notch1 and Notch2, transmembrane receptors belonging to the Notch family, are pivotal mediators of intercellular communication and have profound implications including cell fate determination, embryonic development, and tissue homeostasis in various cellular processes. Despite their structural homology, Notch1 and Notch2 exhibit discrete phenotypic characteristics and functional nuances that necessitate their individualized targeting in specific medical scenarios. Aberrant Notch signaling, often driven by the dysregulated activity of one receptor over the other, is implicated under various pathological conditions. Notch1 dysregulation is frequently associated with T-cell acute lymphoblastic leukemia, whereas Notch2 perturbations are linked to B-cell malignancies and solid tumors, including breast cancer. Hence, tailored therapeutic interventions that selectively inhibit the relevant Notch receptor need to be devised to disrupt the signaling pathways driving the specific disease phenotype. In this review, we emphasize the importance of distinct tissue-specific expression patterns, functional divergence, disease-specific considerations, and the necessity to minimize off-target effects that collectively underscore the significance of \"individualized\" targeting for Notch1 and Notch2. This comprehensive review sheds light on the receptor-specific characteristics of Notch1 and Notch2, providing insights into their roles in cellular processes and offering opportunities for developing tailored therapeutic interventions in the fields of biomedical research and clinical practice.","PeriodicalId":11955,"journal":{"name":"European Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142617492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Loss in Overall and Quality-Adjusted Life Expectancy for Patients With Chronic-Phase Chronic Myeloid Leukemia. 慢性期慢性髓性白血病患者总体预期寿命和质量调整后预期寿命的损失。

IF 2.3 3区医学

European Journal of Haematology Pub Date : 2024-11-06 DOI: 10.1111/ejh.14328

Enoch Yi-Tung Chen, Torsten Dahlén, Leif Stenke, Magnus Björkholm, Shuang Hao, Paul W Dickman, Mark S Clements

{"title":"Loss in Overall and Quality-Adjusted Life Expectancy for Patients With Chronic-Phase Chronic Myeloid Leukemia.","authors":"Enoch Yi-Tung Chen, Torsten Dahlén, Leif Stenke, Magnus Björkholm, Shuang Hao, Paul W Dickman, Mark S Clements","doi":"10.1111/ejh.14328","DOIUrl":"https://doi.org/10.1111/ejh.14328","url":null,"abstract":"The introduction of tyrosine kinase inhibitors has considerably improved the life expectancy (LE) for patients with chronic myeloid leukemia (CML). Evaluating health-related quality of life within the treatment pathway remains crucial. Using the Swedish CML register, we included 991 adult patients with chronic-phase (CP) CML diagnosed 2007 to 2017, with follow-up until 2018. We developed a multistate model to estimate the loss in LE (LLE) and loss in quality-adjusted life expectancy (LQALE) for the patient population compared to the general population, along with the respective proportions of losses relative to the general population. All patients with CP-CML had a relatively low reduced LE but with larger LQALE. The maximum LLE within age/sex subgroups was 5.7 years (general population LE: 43.2 years vs. CP-CML LE: 37.5 years) for females diagnosed at age 45 years, with LQALE of 12.0 quality-adjusted life years (QALYs) (general population QALE: 38.2 QALYs vs. CP-CML QALE: 26.3 QALYs). Across all ages, the proportions of LLE ranged from 9% to 15%, and the proportions of LQALE were 29% to 33%. Despite a low LLE, our findings reveal a greater LQALE for patients with CP-CML. Further improvements in management of CP-CML are thus warranted to successfully address the prevailing medical needs.","PeriodicalId":11955,"journal":{"name":"European Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142582389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Risk of Cardiovascular Disease in Patients With Classical Hodgkin Lymphoma: A Danish Nationwide Register-Based Cohort Study. 经典霍奇金淋巴瘤患者的心血管疾病风险：丹麦全国登记队列研究》。

IF 2.3 3区医学

European Journal of Haematology Pub Date : 2024-11-06 DOI: 10.1111/ejh.14334

Sissel J Godtfredsen, Harman Yonis, Joachim Baech, Nour R Al-Hussainy, Signe Riddersholm, Lars Kober, Morten Schou, Jacob Haaber Christensen, Martin Hutchings, Rasmus Bo Dahl-Sørensen, Peter Kamper, Caroline E Dietrich, Mikkel Porsborg Andersen, Christian Torp-Pedersen, Peter Sogaard, Tarec Christoffer El-Galaly, Kristian H Kragholm

{"title":"Risk of Cardiovascular Disease in Patients With Classical Hodgkin Lymphoma: A Danish Nationwide Register-Based Cohort Study.","authors":"Sissel J Godtfredsen, Harman Yonis, Joachim Baech, Nour R Al-Hussainy, Signe Riddersholm, Lars Kober, Morten Schou, Jacob Haaber Christensen, Martin Hutchings, Rasmus Bo Dahl-Sørensen, Peter Kamper, Caroline E Dietrich, Mikkel Porsborg Andersen, Christian Torp-Pedersen, Peter Sogaard, Tarec Christoffer El-Galaly, Kristian H Kragholm","doi":"10.1111/ejh.14334","DOIUrl":"https://doi.org/10.1111/ejh.14334","url":null,"abstract":"Risk of cardiovascular disease (CVD) in patients with classical Hodgkin lymphoma (cHL) undergoing contemporary treatment is unclear. cHL patients ≥ 18 years at diagnosis treated with doxorubicin-containing chemotherapy between 2000 and 2022 were matched 1:5 with comparators on birth year, sex, and Charlson Comorbidity Index at time of matching (score of 0 or ≥ 1). Cause-specific cumulative incidence of a composite of CVDs with corresponding 95% confidence intervals (CIs) were computed with death and lymphoma relapse as competing events (i.e., by censoring individuals at such occurrences) using the Aalen-Johansen estimator. A total of 1905 patients and 9525 comparators with a median follow-up of 10 years (interquartile range, [IQR]: 5.9-17.4). Median age was 39 years (IQR: 27-56), median cumulative doxorubicin dose was 250 mg/m2 (IQR: 200-300). The CVD cumulative incidences were 4.7% (95% CI: 3.6-5.7) for patients versus 2.6% (95% CI: 2.3-2.9) for comparators at 5 years, 8.9% (95% CI: 7.2-10.5) versus 5.5% (95% CI: 4.9-6.0) at 10 years, and 17.0% (95% CI: 14.1-19.9) versus 8.2% (95% CI: 7.4-9.0) at 15 years. CVD remains a substantial effect after contemporary treatment for cHL, suggesting that awareness of symptoms and a low threshold for referral to diagnostic examination are still important measures during survivorship.","PeriodicalId":11955,"journal":{"name":"European Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142582345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Biomarkers to Differentiate Acute Chest Syndrome From Vaso-Occlusive Crisis in Children With Sickle Cell Disease. 区分镰状细胞病儿童急性胸部综合征和血管闭塞性危象的生物标志物

IF 2.3 3区医学

European Journal of Haematology Pub Date : 2024-11-05 DOI: 10.1111/ejh.14342

Karen Wang, Nelida Olave, Saurabh Aggarwal, Joo-Yeun Oh, Rakesh P Patel, A K M Fazlur Rahman, Jeffrey Lebensburger, Ammar Saadoon Alishlash

{"title":"Biomarkers to Differentiate Acute Chest Syndrome From Vaso-Occlusive Crisis in Children With Sickle Cell Disease.","authors":"Karen Wang, Nelida Olave, Saurabh Aggarwal, Joo-Yeun Oh, Rakesh P Patel, A K M Fazlur Rahman, Jeffrey Lebensburger, Ammar Saadoon Alishlash","doi":"10.1111/ejh.14342","DOIUrl":"10.1111/ejh.14342","url":null,"abstract":"Background: Acute Chest Syndrome (ACS) is the leading cause of death in children with sickle cell disease (SCD) in the US-about half of the children who develop ACS present initially with pain.Methods: Here, we studied biomarkers to differentiate ACS from vaso-occlusive crises (VOC) in children with SCD who presented with pain to the emergency department (ED). We conducted a prospective cohort study of consecutive patients who presented to the ED with pain and were discharged with ACS or VOC between March, 2017 and February, 2020.Results: We identified 7 patients with ACS and 19 patients with VOC. The two groups were comparable in age and sex. All patients with ACS had asthma versus 42% of the VOC group. The ACS group had lower weight and BMI z-scores. Patients with ACS compared to VOC had significantly higher respiratory rates, lower O2 saturation, and longer hospital stays. They also had higher white blood cell count, glucose level (> 99 mg/dL), anion gap (> 9 mEq/L), sPLA2 (> 7 pg/mL), IFN-γ (> 17.8 pg/mL), IL-10 (1.54 pg/mL), and IL-12 (> 0.5 pg/mL) levels.Conclusions: We identified biomarkers associated with ACS development in children with SCD presenting with pain that allow for earlier ACS interventions to reduce mortality and morbidity.","PeriodicalId":11955,"journal":{"name":"European Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142575363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Featured Cover 精选封面

IF 2.3 3区医学

European Journal of Haematology Pub Date : 2024-11-05 DOI: 10.1111/ejh.14344

Eric J. Niesor, Anne Perez, Serge Rezzi, Andrew Hodgson, Stephane Canarelli, Gregoire Millet, Tadej Debevec, Claire Bordat, Elie Nader, Philippe Connes

引用次数: 0

Inferior Overall Survival After Haploidentical Donor Lymphocyte Infusions in Relapsed Myeloid Neoplasms. 复发性髓系肿瘤患者接受同种异体淋巴细胞输注后的总体生存率较低。

IF 2.3 3区医学

European Journal of Haematology Pub Date : 2024-11-05 DOI: 10.1111/ejh.14340

Tobias Matthieu Benoit, Adrian Bachofner, Nathan Wolfensberger, Yvonne Zaugg-Berger, Markus Gabriel Manz, Dominik Schneidawind

{"title":"Inferior Overall Survival After Haploidentical Donor Lymphocyte Infusions in Relapsed Myeloid Neoplasms.","authors":"Tobias Matthieu Benoit, Adrian Bachofner, Nathan Wolfensberger, Yvonne Zaugg-Berger, Markus Gabriel Manz, Dominik Schneidawind","doi":"10.1111/ejh.14340","DOIUrl":"https://doi.org/10.1111/ejh.14340","url":null,"abstract":"Objectives: Allogeneic hematopoietic stem cell transplantation (HSCT) effectively treats high-risk myeloid neoplasms, but relapses post-HSCT, particularly in acute myeloid leukemia (AML) and myelodysplastic neoplasms (MDS), pose significant challenges. Donor lymphocyte infusion (DLI) has been utilized, but its effectiveness, especially in haploidentical settings, remains insufficiently clarified, and graft-versus-host disease (GvHD) poses a substantial risk.Methods: In this retrospective cohort study, 57 patients with AML or MDS who received DLI after allogeneic HSCT at our center from 2002 to 2023 were analyzed. Herein, only preemptively or therapeutically applied DLI were included, and endpoints included overall survival (OS), progression-free survival (PFS), and GvHD incidence post-DLI.Results: Median OS after DLI was 517 days, with a 1-year OS of 62.5%. Factors associated with longer OS included patient age, HLA-identical donor, post-HSCT treatment naivety, and preemptive DLI indication. Haploidentical DLI was associated with inferior OS compared to HLA-identical DLI; however, PFS and GvHD incidence post-DLI did not differ significantly.Conclusions: Our study findings indicate that OS rate is inferior in patients with relapsed AML or MDS treated with haploidentical DLI in comparison to those who received HLA-identical DLI. Given the limitations of haploidentical DLI, alternative strategies, such as higher cell doses or combination treatment approaches, warrant further investigation.","PeriodicalId":11955,"journal":{"name":"European Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142582382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immunophenotyping for the Assessment of Asymptomatic Lymphocytosis: A Retrospective Analysis and National Survey. 用于评估无症状淋巴细胞增多症的免疫分型：回顾性分析和全国调查

IF 2.3 3区医学

European Journal of Haematology Pub Date : 2024-11-04 DOI: 10.1111/ejh.14336

Tanya Freeman, Peter Johnstone, Stephen P Hibbs, Esubalew Assefa, Shamzah Araf, Timothy Farren, Tom Butler

{"title":"Immunophenotyping for the Assessment of Asymptomatic Lymphocytosis: A Retrospective Analysis and National Survey.","authors":"Tanya Freeman, Peter Johnstone, Stephen P Hibbs, Esubalew Assefa, Shamzah Araf, Timothy Farren, Tom Butler","doi":"10.1111/ejh.14336","DOIUrl":"https://doi.org/10.1111/ejh.14336","url":null,"abstract":"Asymptomatic lymphocytosis poses a common challenge in haematology. Immunophenotyping can establish whether a clonal population is present, but it is expensive and the benefit of diagnosing asymptomatic patients is unproven. This study aimed to establish data to guide the use of immunophenotyping. We analysed the proportion of lymphocytosis in full blood count (FBC) samples across a five-year period within a large UK National Health Service (NHS) trust. Persistent lymphocytosis was present in 0.18% (437/242678) of repeat community samples. Of samples sent for immunophenotyping, 743/784 (95%) with a lymphocyte count > 10 × 109/L had a clonal population, compared to 223/1696 (14%) with a lymphocyte count < 5 × 109/L. We followed up a longitudinal cohort of asymptomatic patients with clonal lymphocytosis to determine how many required treatment. The minority (11/46) of patients needed treatment within 9 years of follow-up. Of patients needing treatment, 10/11 (91%) had a presenting lymphocyte count > 10 × 109/L. In all cases, treatment was initiated when the patient became symptomatic. We propose a lymphocyte count threshold of > 10 × 109/L for referral and immunophenotyping in patients with asymptomatic lymphocytosis. This approach aims to balance safety and cost-effectiveness and reflects uncertainty in the value of diagnosis for asymptomatic patients.","PeriodicalId":11955,"journal":{"name":"European Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142567840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Daratumumab in the Management of Red Cell Aplasia Following Allogeneic Hematopoietic Stem Cell Transplantation. 达拉单抗用于治疗异基因造血干细胞移植后的红细胞增生症。

IF 2.3 3区医学

European Journal of Haematology Pub Date : 2024-11-04 DOI: 10.1111/ejh.14341

Nihar Desai, Auro Viswabandya, Dennis Dong Hwan Kim, Jeffrey H Lipton, Jonas Mattsson, Arjun Datt Law

{"title":"Daratumumab in the Management of Red Cell Aplasia Following Allogeneic Hematopoietic Stem Cell Transplantation.","authors":"Nihar Desai, Auro Viswabandya, Dennis Dong Hwan Kim, Jeffrey H Lipton, Jonas Mattsson, Arjun Datt Law","doi":"10.1111/ejh.14341","DOIUrl":"https://doi.org/10.1111/ejh.14341","url":null,"abstract":"Pure red cell aplasia (PRCA) is a rare but significant complication following major ABO-incompatible allogeneic hematopoietic stem cell transplantation (HSCT). The persistence of recipient B lymphocytes producing anti-donor isohemagglutinins leads to reticulocytopenia and anemia, often resulting in transfusion dependence. Current treatment options for post-HSCT PRCA are limited and frequently yield suboptimal responses, complicating patient management. Herein, we report three cases of post-HSCT PRCA successfully managed with daratumumab, a monoclonal antibody targeting CD38-expressing plasma cells. All patients demonstrated rapid reticulocyte recovery and transfusion independence after daratumumab treatment, despite prior treatment failures. These findings suggest that daratumumab may provide a more effective therapeutic approach, with a favorable safety profile compared to traditional therapies. Given its demonstrated efficacy and safety, daratumumab warrants consideration as a first-line treatment for post-HSCT PRCA, potentially improving patient quality of life and reducing transfusion-related complications. Further studies should explore optimal dosing and long-term outcomes.","PeriodicalId":11955,"journal":{"name":"European Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142567828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0